Neutral-weight HOLD with $63.00 stop and explicit add/reduce triggers based on 200 SMA defense
All three analysts converge on HOLD because: (1) 200 SMA at $64.16 has not been broken, so preemptive exit is reactive; (2) fundamentals intact enough that forced exit is unnecessary; (3) technical damage is real enough that adding is premature; (4) dividend makes the wait productive; (5) next 30-60 days will resolve via either confirmed bounce or breakdown. Price target remains $70.88.
| Position | Action |
|---|---|
| Current position at full defensive weight | Reduce to NEUTRAL model-weight (per 8/10 MO lesson on alpha-drag) |
| Close below $63.00 on volume >15M | Trim 50% position |
| Close below $60 | Full exit |
A 13% pullback in Altria from its recent highs represents a discounted entry opportunity into a high-yield, cash-generating compounder with a credible smoke-free growth pivot, supported by 50+ years of dividend growth, 11x forward P/E valuation, and RSI at 32.2 that historically signals buying opportunities within 30-90 days.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $68.06 | bearish |
| 50 SMA | $70.88 | bearish |
| 200 SMA | $64.16 | bullish |
| RSI (14) | 32.21 | neutral |
| MACD | -1.46 | bearish |
| MACD Signal | -0.74 | bearish |
| MACD Histogram | -0.72 | bearish |
| Bollinger Upper Band | $77.00 | neutral |
| Bollinger Middle Band | $70.65 | bearish |
| Bollinger Lower Band | $64.30 | bullish |
| ATR (14) |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
The smoke-free pivot has moved from promise to execution with verifiable FDA approvals and nationwide distribution
↩ rebuts: “Bear's 'secular tobacco decline' thesis anchored in 2015 mindset”
EV: ~12-15% (Base Case: $72-75, ~12-15% upside); ~23% (Bull Case: $80+, ~23% upside) · concedes: Cigarette volumes are declining 4-5% annually (though pricing power is offsetting volume decline); FDA risk remains — menthol ban and flavor restrictions could materialize; Negative book value deters some institutional buyers (though market has spoken at $108B market cap); RSI at 32.2 and MACD bearish — technical indicators are bearish in the short term; Stock down 9.4% over 30 days
MO is a structurally declining business with a smoke-free pivot too late, too small, and too wounded by the $1.26 billion NJOY impairment to offset secular decline of the core cigarette franchise.
EV: +7.4% (price appreciation over 12 months, with 6.5% dividend bringing total return to ~14%, but with substantial path-dependent risk) · concedes: The 50-year dividend track record is real and the 6.47% yield is a genuine income generator; The smoke-free pivot is real and on! has FDA authorization; Current yield premium above Treasuries provides some near-term support; Q2 2026 reported revenue was slightly above consensus expectations
→ vs conservative: 200 SMA test and breakaway gap concerns are overblown — rising 200 SMA ($62.36 to $64.16) creates rising floor, not crumbling ceiling; $1.26B NJOY impairment already in rearview mirror
→ vs neutral: Waiting for 10 EMA reclaim at $68 or 50 SMA at $70.88 confirmation means missing first 5%+ of recovery move; discipline matters but inaction is costly in asymmetric setups
| $1.96 |
| neutral |
| VWMA | $69.45 | bearish |
Support: 64.3 · 64.16 · 62 · 62.5 | Resistance: 68.06 · 70.65 · 70.88 · 77
MO is in a sharp short-term downtrend following a gap-down breakdown on 2026-07-30 from $74.92, with price now testing the critical $64.16–$64.30 support zone (200 SMA / lower Bollinger Band convergence). The primary uptrend remains intact but is under serious pressure; a decisive break below $64 would be a major bearish development. HOLD is recommended pending reversal confirmation (10 EMA reclaim at $68.06 with MACD histogram bottoming); existing holders should tighten stops to ~$63.50. RSI approaching oversold at 32.21 but can remain depressed in strong downtrends; watch for either a washout below 30 or a bounce with volume confirmation.
Market Cap
$108.58 billion
Beta
0.495
Dividend Yield
6.47%
P/E Ratio (TTM)
13.69
Forward P/E
11.09
EPS (TTM)
$4.75
Forward EPS
$5.86
Estimated Annual Dividend
~$4.32/share
Payout Ratio
~91% of TTM EPS
2025 Total Revenue
$20,139M
2025 Gross Profit
$14,542M
2025 Operating Income
$9,899M
2025 Net Income
$6,947M
2025 Diluted EPS
$4.12
2025 Normalized Net Income (excl. special items)
~$8.5B
Q2 2026 Net Revenue
$5,356M
Q2 2026 Operating Income
$3,157M
Q2 2026 Net Income
$2,298M
Q2 2026 Diluted EPS
$1.37
Q2 2026 Operating Margin
~59%
Net Margin (TTM)
39.0%
Operating Margin (TTM)
61.5%
Gross Margin
87.2%
ROA
29.5%
2025 Free Cash Flow
$9,074M
2025 Operating Cash Flow
$9,290M
2025 Capex
($216M)
2025 Dividends Paid
$6,960M
2025 Buybacks
$1,000M
Cash & Equivalents (Jun 2026)
$2,367M
Total Debt
$24,577M
Net Debt
$22,210M
Net Debt / FCF
~2.4x
Total Assets (Jun 2026)
$33,374M
Stockholders' Equity
($2,668M)
Goodwill & Intangibles
$17,637M
Current Ratio
0.518
Working Capital
($3,748M)
52-Week High
$77.06
52-Week Low
$54.70
50-Day Moving Average
$71.18
200-Day Moving Average
$65.66
Price/Book
-40.69
PEG Ratio
1.49
Years of Consecutive Dividend Increases
>50 years
Strengths
Concerns
Altria Group (MO) is a large-cap consumer defensive company generating approximately $9B in annual free cash flow with a 6.47% dividend yield and over 50 years of consecutive dividend increases, supported by a dominant Marlboro franchise (~40% U.S. cigarette market share) and industry-leading operating margins of 61.5%. The company trades at a forward P/E of 11.09x with Q2 2026 showing strong operating performance at 59% operating margins, though 2025 earnings were depressed by a $1.26B NJOY-related impairment and normalized net income was approximately $8.5B. Key risks include secular cigarette volume declines, negative book value from aggressive buybacks, high payout ratio of 91%, and regulatory/litigation headwinds, while strategic positives include the NJOY e-vapor acquisition and on! nicotine pouch growth in reduced-risk products.
Macro: Higher-for-longer rate regime with 86% Polymarket-implied probability of zero Fed cuts in 2026 (+3.0pp conviction week-over-week); soft-landing consensus with only 8% recession probability (−1.0pp). Sticky above-target inflation with oil-led upside risk as US–Iran peace optimism fades. Defensive rotation dominant theme with stocks fading two straight sessions into Aug 11; consumers still spending despite uncertainty — constructive for branded consumer staples with pricing power. 0% probability of 6+ Fed cuts in 2026.